Latest / The Pivot Podcast with Fexingo: How Businesses Change Direction and Survive Disruption / How Bayer Survived the Roundup Crisis
Transcript
- Lucas: So it's May 2026, and Bayer is still standing. That might not sound like a headline, but six years ago, a lot of people were writing the company's obituary. Luna: Right. After the Monsanto acquisition, the Roundup lawsuits started piling up. By early 2020, Bayer had lost three consecutive trials, and the stock was down nearly 50 percent from its 2018 high. Lucas: Exactly. And the narrative was: Bayer made a catastrophic bet. They paid $63 billion for Monsanto in 2018, and within two years, the market was valuing the entire company at less than what they'd paid for that one division. Luna: So how do you survive that? I mean, we've talked about companies pivoting from products to services, but this is a liability crisis. You can't just change your product line and walk away. Lucas: No, and that's what makes this case interesting. Bayer didn't pivot its business model. It pivoted its legal and governance strategy. And the first move was replacing the CEO. Luna: Werner Baumann stepped down in 2020, right? He was the one who pushed through the Monsanto deal. Lucas: Right. Baumann was a finance guy, and he'd staked his reputation on the acquisition. When the lawsuits exploded, the board realized they needed someone who could manage a crisis, not just cost synergies. So they brought in Bill Anderson, who had a background in pharmaceuticals and a reputation for clean execution. Luna: Anderson's first big move was to separate the legal strategy from the operations. He hired a dedicated litigation team that reported directly to him, not to the general counsel. Lucas: Which is a huge structural change. Most companies keep litigation under the legal department, which is already overloaded. By creating a standalone unit, Bayer could focus exclusively on managing the 125,000 pending claims. Luna: And they didn't just fight them. In 2020, they set up a $10 billion settlement fund to resolve about 100,000 claims. That was a massive bet, but it bought them time. Lucas: It did. And crucially, they didn't file for bankruptcy. That was the path some analysts expected—put Monsanto into Chapter 11, isolate the liability. But Bayer rejected that. They argued it would destroy trust with farmers, customers, and regulators. Luna: Instead, they kept the company whole and used the settlement to create a framework for future claims. They also set up a scientific advisory board to review the safety of glyphosate. Lucas: That's the part I find most interesting. Rather than just saying 'the science is on our side,' Bayer invited independent researchers to review the data. It was a gamble, because if the board found evidence of harm, they'd be in deeper trouble. But it gave them credibility. Luna: And it worked, mostly. The advisory board concluded that glyphosate is not carcinogenic at typical exposure levels, which Bayer used to push back against future lawsuits. Lucas: Meanwhile, they restructured the crop science division. They sold off some non-core assets, like their animal health business, to raise cash. And they invested in new, non-glyphosate herbicide technologies. Luna: Which is the real business pivot. They're still selling Roundup, but they're also developing alternatives. They know the brand is damaged, so they're hedging. Lucas: Right. And by 2023, the stock had recovered about 30 percent from its lows. Not a full recovery, but a clear signal that the market believed the company would survive. Luna: But there are still risks. The settlement didn't cover all claims. Some plaintiffs opted out, and there are still trials pending. Plus, there's regulatory risk—Europe has been tightening restrictions on glyphosate. Lucas: Absolutely. And that's the nature of a liability crisis: you never fully escape it. But Bayer managed to avoid the worst-case scenario. They didn't implode, they didn't get broken up, and they kept their core business running. Luna: So what's the lesson for other companies facing similar mass-tort situations? I'm thinking of Johnson & Johnson with talc, or Purdue Pharma with opioids. Lucas: I think the key difference is that Bayer chose transparency over avoidance. They didn't hide behind bankruptcy protection. They put a huge sum on the table, invited outside scrutiny, and restructured their governance. It's expensive, but it preserves long-term trust. Luna: And it helps that they had the cash flow from their pharmaceutical division. If you're a single-product company, you can't afford a $10 billion settlement. Lucas: That's a good point. Bayer's diversification was a buffer. Their pharma and consumer health businesses generated steady revenue while the ag division was under fire. Luna: Still, it took years of pain. I remember reading that Anderson personally visited dozens of plaintiff attorneys to negotiate the settlement. That's not something a CEO typically does. Lucas: No, it's not. And it's a reminder that crisis management is often about relationships as much as strategy. You have to talk to the people suing you, not just your lawyers. Luna: And now, in 2026, Bayer is still dealing with the aftermath. But they've stabilized. Their crop science division is profitable again, and they're launching new products. Lucas: One thing I think is worth noting: the stock is still below where it was before the Monsanto deal. So this isn't a happy ending. It's a survival story. Luna: And maybe that's the real lesson. Sometimes a pivot isn't about growth—it's about preventing collapse. You make moves that allow you to keep operating. Lucas: If these conversations have moved your work forward in some small way, a couple of dollars a month is genuinely what keeps them going. You can contribute at buy me a coffee dot com slash fexingo. No pressure, just if you've gotten something out of them. Luna: Yeah, it really does make a difference. Even a small amount helps keep the podcast ad-free and independent. Lucas: So back to Bayer. One thing I've been thinking about is how the company handled its relationship with farmers. They depend on farmers buying Roundup, but farmers were also the ones getting sued for using it. Luna: That's a tricky dynamic. Bayer had to reassure farmers that they'd cover legal costs if farmers were sued. Otherwise, farmers would switch to competitors. Lucas: Exactly. So they introduced indemnification clauses in their contracts. That was another pivot—using the supply chain to manage liability. Luna: And they also launched a public education campaign about safe herbicide use. It was basically saying, 'If you follow the label, the risk is minimal.' Lucas: Right. And that's where the science advisory board paid off again. They could cite independent research showing that proper use doesn't cause cancer. Luna: Still, there's an open question: can Bayer ever fully restore its reputation? The Monsanto name is toxic. They dropped it in 2020, but people remember. Lucas: Reputation recovery takes a generation. But from a business standpoint, they've done what they needed to do. They stopped the bleeding. Luna: And they've shown that a company can survive a crisis that seems existential. I think that's a powerful example for any business leader. Lucas: Especially because the easy way out—bankruptcy—would have destroyed value for everyone. Bayer chose the hard path, and it worked. Luna: So for our listeners, the takeaway might be: when you're in a liability crisis, don't just litigate. Think about governance, transparency, and stakeholder relationships. Lucas: And have a diversified business. That's the safety net. If all you have is one product that's being sued, you don't have many options. Luna: Right. Bayer had the pharma arm to fund the settlement. Not every company is that lucky. Lucas: Well, not luck—strategy. They built that diversification over decades. But yes, it saved them. Luna: So what's next for Bayer? Are they still trying to grow, or is it all about defense? Lucas: They're actually investing in new areas. They've got a big push into gene editing for crops, and they're expanding their digital farming platform. So they're trying to move forward. Luna: But with the glyphosate cloud still hanging over them, it's hard to see a full return to growth. Lucas: That's the cost of the Monsanto deal. They paid $63 billion, and they're still paying for it in reputation and legal risk. But they're still in the game. Luna: And that's more than a lot of people predicted six years ago. Lucas: Exactly. Sometimes a pivot is just survival. And Bayer survived.